In recent years, some MEK inhibitors and Raf/B-Raf inhibitors, able to block Ras-ERK signalling in vivo, have already been tested clinically for cancer therapy (Uehling and Harris, 2015; Wu and Park, 2015). This evidence concerns the gene BRAF and cancer.